Incretin receptor agonists are among the most actively studied compounds in metabolic research. This class acts at receptors involved in glucose regulation and energy balance, and researchers use these peptides to investigate signaling in controlled in vitro and preclinical models.
The receptors involved
GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) are incretin receptors that participate in metabolic signaling. Agonists of these receptors are studied for how they modulate those pathways.
Compounds in this class
- Semaglutide — a long-acting GLP-1 receptor agonist studied in glycemic-signaling research.
- Tirzepatide — a dual GIP/GLP-1 receptor agonist used to study multi-receptor metabolic signaling.
- Retatrutide — a triple GIP/GLP-1/glucagon receptor agonist investigated in multi-pathway metabolic models.
Each is supplied as a lyophilized powder with a batch-specific COA documenting identity and purity.
Research Use Only. V8 Peptides products are supplied strictly for laboratory research and development and are not intended for human or veterinary use, consumption, or any therapeutic or diagnostic purpose.